Ouro Fino Saúde Animal Participações S.A (OFSA3) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Ouro Fino Saúde Animal Participações S.A (OFSA3) has a cash flow conversion efficiency ratio of 0.166x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (R$135.27 Million ≈ $26.54 Million USD) by net assets (R$816.49 Million ≈ $160.21 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Ouro Fino Saúde Animal Participações S.A (OFSA3) balance sheet quality index to measure how much of total assets are equity-financed.
Ouro Fino Saúde Animal Participações S.A - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how Ouro Fino Saúde Animal Participações S.A's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Ouro Fino Saúde Animal Participações S.A cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Ouro Fino Saúde Animal Participações S.A Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ouro Fino Saúde Animal Participações S.A ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Z Squared Inc.
NASDAQ:ZSQR
|
-0.095x |
|
G.M.I Technology Inc
TW:3312
|
0.000x |
|
New Power Plasma Co.Ltd
KQ:144960
|
0.051x |
|
Lingnan Landscape Co Ltd
SHE:002717
|
-0.002x |
|
Hefei Jingsong Intelligent Technology Co. Ltd. A
SHG:688251
|
N/A |
|
Shenzhen New Land Co Ltd
SHE:300778
|
0.003x |
|
Dalian Friendship Group Co Ltd
SHE:000679
|
-0.543x |
|
NEOBO FASTIGHETER
ST:NEOBO
|
0.006x |
Annual Cash Flow Conversion Efficiency for Ouro Fino Saúde Animal Participações S.A (2011–2025)
The table below shows the annual cash flow conversion efficiency of Ouro Fino Saúde Animal Participações S.A from 2011 to 2025. For the full company profile with market capitalisation and key ratios, see Ouro Fino Saúde Animal Participações S.A (OFSA3) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | R$796.86 Million ≈ $156.36 Million |
R$99.91 Million ≈ $19.60 Million |
0.125x | +28.27% |
| 2024-12-31 | R$756.40 Million ≈ $148.42 Million |
R$73.94 Million ≈ $14.51 Million |
0.098x | -64.59% |
| 2023-12-31 | R$689.39 Million ≈ $135.27 Million |
R$190.30 Million ≈ $37.34 Million |
0.276x | +126.76% |
| 2022-12-31 | R$735.95 Million ≈ $144.41 Million |
R$89.59 Million ≈ $17.58 Million |
0.122x | +67.93% |
| 2021-12-31 | R$641.45 Million ≈ $125.86 Million |
R$46.50 Million ≈ $9.12 Million |
0.072x | -63.68% |
| 2020-12-31 | R$560.78 Million ≈ $110.03 Million |
R$111.94 Million ≈ $21.96 Million |
0.200x | +74.32% |
| 2019-12-31 | R$492.45 Million ≈ $96.63 Million |
R$56.39 Million ≈ $11.06 Million |
0.115x | +21.96% |
| 2018-12-31 | R$455.94 Million ≈ $89.46 Million |
R$42.81 Million ≈ $8.40 Million |
0.094x | -61.70% |
| 2017-12-31 | R$405.88 Million ≈ $79.64 Million |
R$99.50 Million ≈ $19.52 Million |
0.245x | +118.41% |
| 2016-12-31 | R$376.33 Million ≈ $73.84 Million |
R$42.24 Million ≈ $8.29 Million |
0.112x | +175.25% |
| 2015-12-31 | R$380.31 Million ≈ $74.62 Million |
R$15.51 Million ≈ $3.04 Million |
0.041x | +1478.41% |
| 2014-12-31 | R$330.16 Million ≈ $64.78 Million |
R$853.00K ≈ $167.37K |
0.003x | -98.38% |
| 2013-12-31 | R$209.42 Million ≈ $41.09 Million |
R$33.45 Million ≈ $6.56 Million |
0.160x | -6.07% |
| 2012-12-31 | R$194.84 Million ≈ $38.23 Million |
R$33.13 Million ≈ $6.50 Million |
0.170x | +114.04% |
| 2011-12-31 | R$177.44 Million ≈ $34.82 Million |
R$14.10 Million ≈ $2.77 Million |
0.079x | -- |
About Ouro Fino Saúde Animal Participações S.A
Ouro Fino Saúde Animal Participações S.A., together with its subsidiaries, engages in the development, production, and sale of veterinary drugs, vaccines, and other products for production and companion animals primarily in Brazil. The company operates through three segments: Production Animals; Companion Animals; and International Operations. It manufactures and trades in medicines, including an… Read more